Xenetic Biosciences (NASDAQ:XBIO) Releases Earnings Results

Xenetic Biosciences (NASDAQ:XBIO) announced its quarterly earnings results on Thursday. The company reported ($0.41) earnings per share for the quarter, FiscalAI reports. The business had revenue of $0.66 million during the quarter. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.

Xenetic Biosciences Stock Performance

Xenetic Biosciences stock opened at $2.85 on Friday. The company has a 50 day moving average price of $2.89 and a 200-day moving average price of $2.81. The company has a market capitalization of $6.53 million, a PE ratio of -2.37 and a beta of 2.10. Xenetic Biosciences has a fifty-two week low of $1.90 and a fifty-two week high of $13.93.

Institutional Trading of Xenetic Biosciences

A hedge fund recently raised its stake in Xenetic Biosciences stock. Renaissance Technologies LLC raised its stake in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 516.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 178,509 shares of the company’s stock after acquiring an additional 149,559 shares during the quarter. Renaissance Technologies LLC owned approximately 7.80% of Xenetic Biosciences worth $387,000 at the end of the most recent reporting period. 15.12% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Xenetic Biosciences currently has an average rating of “Sell”.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.